Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Breast Cancer · Ovarian Cancer · Endometrial Cancer · PIK3CA Mutation · HER2- Negative Breast Cancer · Advanced Breast Cancer · Unresectable Solid Tumor · Hormone Receptor Positive Tumor · Cervical Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

START Los Angeles, Los Angeles, California, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
NEXT Houston, Houston, Texas, United States
NEXT San Antonio, San Antonio, Texas, United States
NEXT Virginia, Fairfax, Virginia, United States

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

PIK3CA Mutation · Solid Tumor, Adult · HER2-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Tucson, United States · San Diego, United States

A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Breast Cancer · Solid Tumor

Abroad (travel likely)RecruitingPHASE1

Shanghai, China

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

Advanced Solid Cancer · Metastatic Solid Tumor · Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1

Zhengzhou, China · Shanghai, China

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

Colorectal Cancer · Ovarian Cancer · Gastric Cancer

IsraelRecruitingPHASE1, PHASE2

Jerusalem, Israel